Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Alnylam Pharma (DUL) Stock Price & Analysis
1 Followers
DUL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.95 - €195.40
Previous Close€136.65
Volume0.00
Average Volume (3M)42.00
Market Cap
€17.70B
Enterprise Value€16.64B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)N/A
Beta0.12
Next Earnings
Jul 31, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,945,793
10 Day Avg. Volume0
30 Day Avg. Volume42
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-82.17
Price to Sales (P/S)9.41
Price to Cash Flow (P/CF)-152.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.17
Enterprise Value/Gross Profit10.67
Enterprise Value/Ebitda-61.78
Forecast
1Y Price Target
€212.46Price Target Upside55.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsHELIOS-B is likely to succeed on the primary endpoint—composite of mortality and cardiovascular events vs placebo.
Drug EfficacyZilebesiran achieved clinically meaningful and significant reductions in blood pressure lasting for six months.
Strategic PartnershipThe collaboration with Roche includes a significant financial package that could provide Alnylam with $2.8 billion, bolstering its financial position.
Bears Say
Clinical Trial ConcernsA reduction in enrolled patients may decrease the statistical power of the HELIOS-B trial, which is a concern for investors.
Commercialization ChallengesCommercial positioning of the drug is complicated by payer barriers to combination use, high bars for first-line adoption, and stable disease in many tafamidis patients.
Market CompetitionIncreasing competition in the market could pose challenges for the commercial launch of ALNY's product.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
6.11% Other Institutional Investors
93.89% Public Companies and
Individual Investors
DUL FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was €132.95 and its highest was €195.40 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 89 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 02, 2024. The company reported -€0.485 earnings per share for the quarter, beating the consensus estimate of -€1.042 by €0.556.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alnylam Pharmaceuticals have?
Currently, no data Available
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -€0.485 in its last earnings report, beating expectations of -€1.042. Following the earnings report the stock price went up 1.197%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 703M.
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€212.46 (55.48% Upside)
€212.46 (55.48% Upside)
Blogger Sentiment
Bullish
DE:DUL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.99%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
DUL Company Deck
---
DUL Earnings Call
Q4 2024
0:00 / 0:00
---
DUL Stock 12 Months Forecast
Average Price Target
€212.46
▲(55.48% Upside)
Technical Analysis
Best Analysts Covering DUL
1 Year
1 Year Success Rate
20/33 ratings generated profit
1 Year Average Return
+18.53%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 60.61% of your transactions generating a profit, with an average return of +18.53% per trade.
---